Life sciences briefing: Monday, Dec. 3, 2007

Featured companies: CoMentis, ForHealth Technologies, Merrimack Pharmaceuticals, QuantomiX, Progenitor Cell Therapy, River Diagnostics, Topaz Pharmaceuticals

Life sciences briefing: Thursday, Sept. 27, 2007

Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences

Double vision: Ophthotech, Eyetech and Lux BioSciences

When news that the brand-new startup Ophthotech had raised a $36 million first round broke on Monday, it was clear that the venture amounted to a kind of do-over for officials of the late, unlamented Eyetech Pharmaceuticals. Eyetech, you might recall, burst onto the scene with a rocket-science aptamer-based blindness drug called Macugen and a flashy $157 million IPO, then proceeded to get its head handed to it by even better rocket science from Genentech, and eventually sold itself ignominiously to OSI Pharmaceuticals for a lower share price than its IPO (a deal that apparently worked out even less well for OSI).